NCT06949410

HER2 Vaccine for Locally Advanced Breast Cancer

Phase I Trial of a Chimeric (Trastuzumab-like and Pertuzumab-like) HER2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant for Locally Advanced HER2 Positive Breast Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (estimated)
• Sponsor: Pravin T.P Kaumaya · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.

Conditions

• Breast Cancer
• HER2-positive Breast Cancer

Interventions

Type	Name	Description
DRUG	HER2 Vaccine	MVF-HER2 266-296 and MVF HER2 597-626 peptide vaccines

Timeline

• Start date: 2026-03-01
• Primary completion: 2029-12-01
• Completion: 2030-03-01
• First posted: 2025-04-29
• Last updated: 2025-12-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study